New drug duo targets tough lung cancer mutation

NCT ID NCT07227025

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participants will be enrolled, and the study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ankara Bilkent Sehir Hastanesi
RECRUITING

Çankaya, 06800, Turkey (Türkiye)
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
RECRUITING

Ankara, 06620, Turkey (Türkiye)
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
RECRUITING

Istanbul, 34010, Turkey (Türkiye)
New York University Langone Medical Center
RECRUITING

New York, New York, 10016, United States
NorthWest Medical Specialties, PLLC
SUSPENDED

Puyallup, Washington, 98373, United States
Oncology Consultants Cancer Center
SUSPENDED

Houston, Texas, 77030, United States
Princess Margaret Hospital
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Shanghai East Hospital
RECRUITING

Shanghai, 310000, China
The First Affiliated Hospital Sun Yat sen University
RECRUITING

Guangzhou, 510060, China
University of California Irvine
SUSPENDED

Irvine, California, 92697, United States
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
SUSPENDED

Philadelphia, Pennsylvania, 19104, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG